Clinical trials: Cognitive Ability
Cognitive Functioning of Healthy Individuals, Hispanic
Norms and Validation for IntelliSpace Cognition Spanish Version
This study aims to validate and provide applicable norms for the United States (US) Spanish versions of the IntelliSpace Cognition (ISC) neuropsychological tests.
- Trial name
- NCT05210777
- Testing
- observation
- Where
- 2 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Cognitive Functioning
Efficacy Study of AlphaBRAIN Administered Orally
The manufacturers of AlphaBRAIN(TM) claim that their product, when taken as directed, has beneficial effects on cognition. The active ingredient in AlphaBRAIN, Huperzine A, is a naturally occurring compound found in firmoss and…
- Trial name
- NCT02739139
- Testing
- AlphaBrain
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Onnits Labs, LLC
Healthy
Effect of a Nutritional Approach in Combination With Cognitive Stimulation on Child Cognitive Abilities
The objective of the study is to explore the impact of a combined intervention including a growing up milk (GUM) fortified in micronutrients and cognitive stimulation on cognitive abilities, mother-child- interaction and behavior…
- Trial name
- Stimulearn (NCT02359669)
- Testing
- StimuLearn Intervention, Without StimuLearn intervention
- Where
- Indonesia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Traumatic Brain Injury
NeuroAiD II™ (MLC901) in Mild Traumatic Brain Injury
A Randomized Double-blind, Placebo-controlled, Multi-center Trial to determine the efficacy of NeuroAiD II™ (MLC901) in improvement of cognitive functioning of adult patients with long-term cognitive impairment following mild…
- Trial name
- SAMURAI (NCT04861688)
- Testing
- Traditional Chinese Medicine (NeuroAiD II™ (MLC901)
- Where
- 4 sites in Russia
- Volunteers
- 182 people
- Sponsor
- Moleac Pte Ltd.
Chronic Pain
Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning
The purpose of the study is to determine whether extended-release oxymorphone hydrochloride taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts cognitive functioning, using Cambridge…
- Trial name
- NCT00930943
- Testing
- Oxymorphone ER
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- MedVadis Research Corporation
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5)…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- FUTURE-US (NCT04951284)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
MCI, Cognitive Ability, General
ViewMind Atlas Cognition
The objective of this study is to demonstrate the clinical validity, analytical validity and safety of ViewMind Atlas as an adjunctive tool to be used by healthcare professionals (HCP) evaluating cognitive impairment in adults…
- Conditions
- MCI, Cognitive Ability, General, Cognitive Decline, Cognition
- Trial name
- VM-Cog (NCT06746844)
- Testing
- ViewMind Atlas™
- Where
- Argentina
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- ViewMind
Major Depressive Disorder
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
To the best of the knowledge of the Principal Investigators, there was no randomised controlled trial to assess the potential cognitive improvement seen with Vortioxetine, in comparison with some other most commonly used SNRI…
- Trial name
- VENUS (NCT05104918)
- Testing
- Vortioxetine, Venlafaxine
- Volunteers
- 500 people
- Sponsor
- Scotmann Pharmaceuticals
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Cognitive Function, Memory
The Memory and Cognitive Performance Study
The primary purpose of this study is to evaluate the impact of a novel, neuro-protective and neuro-restorative dietary supplement (Braini®) on standardized memory and cognitive performance parameters.
- Conditions
- Cognitive Function, Memory, Brain Health
- Trial name
- NCT04025255
- Testing
- Braini
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vita Naturel, LLC
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- PAST-US (NCT04937959)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Cognitive Ability, General
Neurodevelopment at 5.5 Years of Age in Children Who Received Infant Formula With Enriched Protein Fractions
This is a follow-up study of a multi-center, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate neurodevelopment at 5.5 years of age and health outcomes through 5.5 years of age…
- Trial name
- NCT04442477
- Testing
- Enriched Protein Fractions, Protein Fraction
- Where
- China
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Alzheimer's Disease
Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease
This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived…
- Trial name
- NCT02054208
- Testing
- human umbilical cord blood derived mesenchymal stem cells, Normal saline 2mL
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Medipost Co Ltd.
Cognitive Functioning of Healthy Individuals
Norms Expansion and Validation for IntelliSpace Cognition
This study aims to expand the normative dataset for Philips IntelliSpace Cognition to include ages 18-49 and 80+ and aims to validate two new digital tests.
- Trial name
- NCT04729257
- Testing
- Philips IntelliSpace Cognition (ISC)., Paper-Pencil Tests.
- Where
- United States
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Cognition
Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment
The objective of this randomized, triple-blind, placebo-controlled clinical trial is to compare NANO-PSO therapy against placebo in improving cognitive abilities in older adults with mild to moderate non-vascular cognitive…
- Trial name
- COGMEG5 (NCT06520878)
- Testing
- NANO-PSO (pomegranate seed oil)
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Distribuidora Biolife SA de CV
Cognitive Functioning of Healthy Individuals
Psychometric Properties of IntelliSpace Cognition
This study aims to validate the tests that are on the IntelliSpace Cognition platform and to establish normative data for these tests.
- Trial name
- NCT03801382
- Testing
- IntelliSpace Cognition (ISC), Paper-Pencil Tests
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Schizophrenia
Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
This will be a phase IV 20 -32 day prospective, double blind, double-dummy, randomised crossover study that will evaluate the effect of quetiapine XR and quetiapine IR on cognitive performance in patients with schizophrenia…
- Trial name
- eXtRa (NCT01213836)
- Testing
- Seroquel XR- quetiapine fumarate extended release, Seroquel IR - quetiapine fumarate
- Where
- 20 sites in Austria, Denmark and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI
Auditory Stimulation During Sleep to Enhance Long-Term Memory in Amnestic MCI
This study aims to evaluate the efficacy and safety of Elevvo AudiStim, a sleep auditory stimulation device, as a symptomatic treatment for patients with amnestic mild cognitive impairment (aMCI).
- Conditions
- Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI, Alzheimer or Mild Cognitive Impairment
- Trial name
- NCT07402590
- Testing
- Auditory Stimulation
- Where
- Spain
- Volunteers
- 37 people
- Sponsor
- Bitbrain